ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $16.43M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$9.09M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $8.53M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$14.61M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $16.43M | (m) | (m) | (m) | $158.00K* | $12.64M* | $10.94M | $20.36M | $82.14M | $136.00K |
| 2026-03-31 | Reported | (m) | -$9.09M | (m) | (m) | (m) | $0.00 | $2.24M | $9.78M | $30.63M | $74.08M | $93.00K |
| 2025-09-30 | Reported | (m) | $8.53M | (m) | (m) | (m) | $0.00* | -$1.75M* | $8.69M | $19.60M | $62.40M | $80.00K |
| 2025-06-30 | Reported | (m) | -$14.61M | (m) | (m) | (m) | $78.00K* | $324.00K* | $7.49M | $19.45M | $69.17M | $342.00K |
| 2025-03-31 | Reported | (m) | -$24.53M | (m) | (m) | (m) | $608.00K | -$30.38M | $8.83M | $17.54M | $64.00M | $279.00K |
| 2024-09-30 | Reported | (m) | -$39.07M | (m) | (m) | (m) | $143.00K* | -$34.69M* | $5.50M | $19.50M | $58.82M | $0.00 |
| 2024-06-30 | Reported | (m) | -$50.08M | (m) | (m) | (m) | $0.00* | -$45.12M* | $3.46M | $19.30M | $58.17M | $0.00 |
| 2024-03-31 | Reported | (m) | -$31.62M | (m) | (m) | (m) | $0.00 | -$31.60M | $3.26M | $23.14M | $54.79M | $324.00K |
| 2023-09-30 | Reported | (m) | -$36.90M | (m) | (m) | (m) | $64.00K* | -$43.98M* | $1.18M | $26.24M | $47.59M | $3.02M |
| 2023-06-30 | Reported | (m) | -$66.76M | (m) | (m) | (m) | $276.00K* | -$66.48M* | $776.00K | $25.22M | $45.96M | $0.00 |
| 2023-03-31 | Reported | (m) | -$76.27M | (m) | (m) | (m) | $82.00K | -$80.34M | $783.00K | $35.34M | $42.92M | $0.00 |
| 2022-09-30 | Reported | (m) | -$104.75M | (m) | (m) | (m) | $6.00K* | -$67.69M* | (m) | $69.73M | $35.47M | $0.00 |
| 2022-06-30 | Reported | (m) | -$65.83M | (m) | (m) | (m) | $80.00K* | -$61.98M* | (m) | $38.20M | $27.62M | (m) |
| 2022-03-31 | Reported | (m) | -$62.63M | (m) | (m) | (m) | $124.00K | -$56.98M | (m) | $40.62M | $22.01M | (m) |
| 2021-09-30 | Reported | (m) | -$57.08M | (m) | (m) | (m) | $137.00K* | -$40.88M* | (m) | $40.60M | $16.47M | (m) |
| 2021-06-30 | Reported | (m) | -$42.08M | (m) | (m) | (m) | $43.00K* | -$35.83M* | (m) | $30.77M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$36.09M | (m) | (m) | (m) | $554.00K | -$46.20M | (m) | $21.63M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$38.30M | (m) | (m) | (m) | $110.00K* | -$33.69M* | (m) | $32.74M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$35.63M | (m) | (m) | (m) | $17.00K* | -$25.76M* | (m) | $30.01M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$28.65M | (m) | (m) | (m) | $41.00K | -$21.01M | (m) | $25.18M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$14.65M | (m) | (m) | (m) | $4.00K* | -$10.72M* | (m) | $12.35M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$8.54M | (m) | (m) | (m) | $42.00K* | -$8.24M* | (m) | $7.21M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$6.95M | (m) | (m) | (m) | $183.00K | -$7.07M | (m) | $6.20M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$12.23M | (m) | (m) | (m) | $686.00K | -$5.63M | $36.70M | $77.05M | $274.55M | $1.17M |
| 2024-12-31 | Reported | (m) | -$128.40M | (m) | (m) | (m) | $143.00K | -$112.16M | $19.13M | $76.42M | $229.39M | $647.00K |
| 2023-12-31 | Reported | (m) | -$241.10M | (m) | (m) | (m) | $428.00K | -$247.06M | $4.99M | $110.58M | $185.15M | $3.11M |
| 2022-12-31 | Reported | (m) | -$301.63M | (m) | (m) | (m) | $333.00K | -$257.71M | $754.00K | $182.44M | $122.12M | $0.00 |
| 2021-12-31 | Reported | (m) | -$206.53M | (m) | (m) | (m) | $995.00K | -$174.63M | $0.00 | $145.56M | $60.97M | $0.00 |
| 2020-12-31 | Reported | (m) | -$136.65M | (m) | (m) | (m) | $321.00K | -$113.03M | (m) | $115.31M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$43.13M | (m) | (m) | (m) | $295.00K | -$42.84M | (m) | $36.52M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$19.73M | (m) | (m) | (m) | $0.00 | -$14.09M | (m) | $17.94M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |